Treatment, overall survival, and costs in patients with<i>ALK</i>-positive non-small-cell lung cancer after crizotinib monotherapy

Abstract

After crizotinib monotherapy, most patients either received radiotherapy only or discontinued antineoplastic treatment altogether. OS after discontinuing crizotinib was poor and shorter among those with brain metastases than without, and among those without subsequent antineoplastic treatment than with. Patients who continued antineoplastic treatment incurred substantial healthcare costs.